A Case of Mitral Valve Replacement Complicated with Essential Thrombocythemia Preoperatively Interrupting Hydroxycarbamide

VernacularTitle:本態性血小板症を合併した僧帽弁置換術前に化学療法を調節した1例
Author: Kazuyoshi HATADA ¹ ; Toshihiro ISHIKAWA ¹ ; Keisuke MIYAJIMA ² ; Masao TAKAHASHI ²
Author Information

1. Department of Cardiovascular Surgery, Odawara Municipal Hospital
2. Department of Cardiovascular Surgery, Hiratsuka Kyosai Heart Center, Hiratsuka Kyosai Hospital
Keywords: essential thrombocythemia; hydroxyurea; mitral valve replacement
From:Japanese Journal of Cardiovascular Surgery 2019;48(6):401-404
CountryJapan
Language:Japanese
Abstract: Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by thrombocytosis and malfunction of platelets. Both thrombosis and bleeding due to thrombocytosis may occur. An 81-year-old female patient complicated with ET underwent mitral valve replacement using a bioprosthetic valve due to severe mitral regurgitation. She had been diagnosed and treated with the hydroxycarbamide for ET. The hydroxycarbamide had been interrupted 14 days before the surgery, to prevent infection and delayed wound healing. At hospitalization for surgery, her platelet count rose to 1,290,000/μl from 790,000/μl. Readministration of a half dose of the hydroxycarbamide lowered the platelets to her original level. During the operation, more heparin was necessary to control activated coagulation time for cardiopulmonary bypass. She was discharged unaffectedly on 25 POD.